ARF6 and breast ductal adenocarcinoma: These observations, together with the aforementioned observations of Arf6 and AMAP1 expression, also suggest that the EGFR-GEP100-Arf6-AMAP1 pathway is frequently used in a substantially large population of primary ductal carcinomas for the development of malignancy.